Weight-loss drugs found to slash cancer death rates

"Weight-loss drugs have been found to dramatically slash death rates in colon cancer patients, according to new research. Patients taking GLP-1 receptors - the class of drugs behind Ozempic, Wegovy and Mounjaro - were less than half as likely to die within five years compared to those who weren't on the drugs, scientists at the University of California San Diego said."

"In an analysis of more than 6,800 colon cancer patients, 15.5 per cent of those on GLP-1 drugs died within five years, compared to 37.1 per cent of those who were not on the drugs. The findings, published in the journal Cancer Investigation, suggest the weight-loss drugs may help reduce inflammation and improve insulin sensitivity, which experts say could explain the link to lower morbidity."

Journalists are being sent to cover reproductive rights, climate change, and Big Tech on the ground, investigating topics such as the financials of a pro-Trump PAC and producing documentaries about American women fighting for reproductive rights. The outlet avoids paywalls and solicits donations to fund reporters speaking to both sides of developing stories. New research finds GLP-1 receptor agonist weight-loss drugs (Ozempic, Wegovy, Mounjaro) linked to much lower five-year mortality among colon cancer patients: 15.5% versus 37.1% in non-users. Possible mechanisms include reduced inflammation, improved insulin sensitivity, and potential direct anti-cancer effects, but further research is required.

Read at www.independent.co.uk